GEN İlaç
↗Ankara, Turkey
GEN is Turkey's leading specialty pharmaceutical company established in 1998, focused on developing and manufacturing innovative therapies for rare diseases and unmet medical needs. The company specializes in orphan drugs and specialty pharmaceuticals across multiple therapeutic areas including oncology, neurology, and endocrinology. With a GMP-certified manufacturing facility spanning 43,000 m² in Ankara and a team of 500+ specialists, GEN operates internationally across multiple continents with offices in Germany, Russia, Kazakhstan, Uzbekistan, and Azerbaijan. The company went public in August 2021 on Borsa Istanbul and continues its commitment to becoming a significant global player in the pharmaceutical industry through R&D investments and strategic partnerships.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharmaceuticals & Orphan Drugs
SIZE & FINANCIALS
Employees:501-1000
Revenue:$XXX-XXXX million estimated
Founded:1997
Ownership:public
Status:operating
FUNDING
Stage:Public
Investors:Public shareholders (22.62% public float)
STOCK
Exchange:Borsa Istanbul
Ticker:GENIL
Market Cap:55-58 billion Turkish Lira
PIPELINE
Stage:Phase 1|Phase 2|Commercial
Lead Drug Stage:Phase 2 (GN-037)
Modalities:Small molecule, Topical formulations, Mitochondria-directed drugs
Active Trials:2
Trial Phases:Phase 1: 1 | Phase 2: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:GEN Pharma Caucasus (Azerbaijan operations), Investment in RS Research (cancer drug platform)
Key Partnerships:Sulfateq BV (SUL-238 development for neurodegenerative diseases), RS Research (cancer drug delivery platform investment), Distribution agreements with: Biogen, Ipsen, Biomarin, Vertex, Orphan Europe, Jaguar Health (Crofelemer commercialization in Turkey and neighboring countries)
COMPETITION
Position:Leader
Competitors:Deva Holding (8.9B TL net sales), Koçak Farma (6.8B TL net sales), Abdi İbrahim, Sanovel, EastPharma, Drogsan Pharmaceuticals, Genveon, Onko İlaç +1 more
LEADERSHIP
Key Executives:
Abidin Gülmüş - Founder and Chairman
Scientific Founders:Abidin Gülmüş
Board Members:Abidin Gülmüş (Chairman), Independent board members (names not publicly disclosed), Global Chief Commercial Officer position exists, Vice President (Foreign Trade), Vice President (R&D & Clinical Operations), Vice President (Strategy & Corporate Development)
LINKS
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of GEN İlaç and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with GEN İlaç. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.